Aurobindo Pharma unveiled plans to develop more than 58 treatments for cancer, as reported Business Standard.
The drugmaker plans to initiate regulatory filings for some assets later this year, with manufacturing starting in 2018 and 2019.
"The portfolio comprises several products with potential first to file opportunities and 180-day market exclusivities," Aurobindo stated.
Meanwhile, in biosimilars, the company aims to commercialise and market assets acquired in its purchase of TL Biopharmaceutical, noting that the treatments could have a market size exceeding $25 billion.
The drugmaker is expecting to start clinical trials of a biosimilar of an anti-angiogenesis drug targeting multiple cancers obtained in the TL acquisition next year.